Bluejay Diagnostics, Inc. BJDX
is a medical diagnostics company focused on improving patient outcomes in critical care settings, with a focus on sepsis. We are working
on developing rapid, near-patient tests using whole blood on our Symphony technology platform ("Symphony"), which consists
of an analyzer and single-use protein detection cartridges. We do not yet have regulatory clearance for Symphony, and we will need to
receive regulatory authorization from the U.S. Food and Drug Administration (the "FDA") before Symphony can be marketed as
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $249.0K | — | — | — |
| Cost of revenue | — | — | — | $200.1K | — | — | — |
| Gross profit | — | — | — | $48.9K | — | — | — |
| R&D | $3.0M | $3.5M | $5.7M | $4.2M | $1.1M | $527.3K | — |
| SG&A | $3.9M | $3.7M | $4.3M | $451.4K | $1.8M | $596.1K | — |
| Total operating expenses | $7.0M | $7.2M | $10.3M | $9.4M | $3.2M | $1.2M | — |
| Operating income | -$7.0M | -$7.2M | -$10.3M | -$9.3M | -$3.2M | -$1.2M | — |
| Interest expense | $839 | $823.0K | — | — | $6.4K | $27.0K | — |
| Net income | -$6.8M | -$7.7M | -$10.0M | -$9.3M | -$3.5M | -$1.2M | — |
| EPS, basic | -15.25 | -456.75 | -3,631.48 | -9.22 | -0.41 | — | — |
| EPS, diluted | -15.25 | -456.75 | -3,631.48 | -9.22 | -0.41 | -0.37 | — |
| Shares, diluted (wtd. avg.) | $449.0K | $45.8K | $2.7K | $1.0M | $8.5M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.2M | $4.3M | $2.2M | $10.1M | $19.0M | $912.4K | $96.0K |
| Inventory | — | — | — | — | — | $84.8K | — |
| Total current assets | $5.5M | $4.9M | $3.2M | $11.8M | $20.7M | $1.1M | — |
| Property, plant and equipment | $1.5M | $1.5M | $1.3M | $1.2M | $337.4K | $459.1K | — |
| Total assets | $7.1M | $6.7M | $4.9M | $13.5M | $21.0M | $1.5M | — |
| Accounts payable | $214.3K | $145.1K | $491.5K | $635.8K | $295.8K | $374.9K | — |
| Total current liabilities | $1.1M | $810.4K | $1.8M | $1.6M | $637.2K | — | — |
| Total liabilities | $1.1M | $927.9K | $2.0M | $2.0M | $637.2K | $1.8M | — |
| Retained earnings | -$41.5M | -$34.7M | -$27.0M | -$17.0M | -$7.7M | -$4.2M | — |
| Total equity | $6.0M | $5.7M | $2.9M | $11.5M | $20.4M | -$4.2M | -$2.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.1M | -$7.8M | -$8.3M | -$7.7M | -$4.4M | -$508.7K | — |
| Depreciation and amortisation | $74.2K | $75.6K | $648.7K | $156.6K | — | — | — |
| Stock-based compensation | $6 | $20.1K | $189.2K | $433.0K | $68.5K | $3.7K | — |
| Capital expenditure | $173.7K | $306.8K | $704.2K | $1.2M | $23.9K | — | — |
| Investing cash flow | -$173.7K | -$306.8K | -$704.2K | -$1.2M | -$23.9K | — | — |
| Financing cash flow | $7.1M | $10.2M | $1.1M | $8.1K | $22.5M | $1.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-024616.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |